Literature DB >> 16409685

Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression.

S J Clark1, S Creighton, M Horner, H M Smith, B Portmann, C Taylor, M E Cramp.   

Abstract

The effect of HIV-related immunosuppression and antiretroviral therapy on the reactivation of latent hepatitis B virus (HBV) infection is unclear. We report four patients with advanced HIV-related immunosuppression and abnormal liver function tests who had evidence of HBV reactivation. Reclearance of hepatitis B occurred in two cases with HIV treatment regimens not containing lamivudine, suggesting that improved immune function may be responsible. In three cases, HBV reactivation was recognized during investigation for abnormal liver function initially attributed to drug toxicity. The possibility of HBV reactivation must be considered in the differential diagnosis of abnormal liver function in cases with advanced HIV.

Entities:  

Mesh:

Year:  2006        PMID: 16409685     DOI: 10.1258/095646206775220612

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  9 in total

1.  Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.

Authors:  S Bagaglio; L Porrino; A Lazzarin; G Morsica
Journal:  Infection       Date:  2010-06-09       Impact factor: 3.553

2.  Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.

Authors:  Abeer Elkady; Sahar Aboulfotuh; Elsayed Mostafa Ali; Douaa Sayed; Nashwa M Abdel-Aziz; Amany M Ali; Shuko Murakami; Sayuki Iijima; Yasuhito Tanaka
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

3.  Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.

Authors:  Andrea Costantini; Katia Marinelli; Giulia Biagioni; Alessia Monachetti; Monica L Ferreri; Luca Butini; Maria Montroni; Aldo Manzin; Patrizia Bagnarelli
Journal:  BMC Infect Dis       Date:  2011-11-04       Impact factor: 3.090

4.  Hepatitis B reactivation after chemotherapy: two decades of clinical research.

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

5.  Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption.

Authors:  S Bagaglio; G Bianchi; A Danise; L Porrino; C Uberti-Foppa; A Lazzarin; A Castagna; G Morsica
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

Review 6.  Liver disease in the HIV-infected individual.

Authors:  Jennifer C Price; Chloe L Thio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

Review 7.  Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Rev Med Virol       Date:  2018-05-15       Impact factor: 6.989

Review 8.  Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-11-18       Impact factor: 3.267

9.  Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.

Authors:  Adam Abdullahi; Olga Mafotsing Fopoussi; Judith Torimiro; Mark Atkins; Charles Kouanfack; Anna Maria Geretti
Journal:  Open Forum Infect Dis       Date:  2018-10-05       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.